Advertisement

Topics

Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500

16:06 EST 8 Nov 2017 | BioPortfolio Report Blog

Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 Pipeline Review, H2 2017


Summary


Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 Lysosomal alphaglucosidase is an enzyme encoded by the GAA gene. It is essential for the degradation of glygogen to glucose in lysosomes. Defects in this gene lead to glycogen storage disease II or Pompe disease.


Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 1, 7 and 1 respectively. Similarly, the universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders which include indications Pompe Disease.


The latest report Lysosomal Alpha Glucosidase Pipeline Review, H2 2017, outlays comprehensive information on the Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 targeted therapeutics development with respective active and dormant or discontinued projects.


The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20

The report reviews Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 targeted therapeutics and enlists all their major and minor projects

The report assesses Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...